Lamotrigine in the treatment of epilepsy in people with intellectual disability.
Lamotrigine tames seizures in clients with ID—just start low, go slow, and track rashes and interactions.
01Research in Context
What this study did
Iivanainen (1998) looked at all published reports on lamotrigine in people with intellectual disability. The author read every paper and wrote a story about how the drug works, how to dose it, and what to watch for. No new data were collected; this is a narrative review.
What they found
Lamotrigine cuts seizure counts in clients with ID. The trick is to start low and raise the dose slowly. Watch for skin rashes and drug interactions, especially with valproate.
How this fits with other research
Reiss et al. (1993) warned that psychiatric labels fail people with ID and urged a brain–behavior lens before any pill. Iivanainen (1998) follows that call by mapping one drug’s real-world use.
Matson et al. (1999) found zero RCT evidence for antipsychotics in the same group. That sounds like a contradiction, but it isn’t: Iivanainen (1998) is about epilepsy, not psychosis, and relied on open studies, not RCTs.
Aznar et al. (2005) showed clozapine can trigger seizures in VCFS/ID. Their single case underlines Iivanainen (1998)’s rule: titrate slowly and monitor closely whenever brain-risk drugs mix.
Why it matters
If you serve adults with ID and epilepsy, you now have a clear playbook. Start lamotrigine at 0.15 mg/kg, increase every two weeks, and check skin and drug list each visit. The same slow-titration rule applies when clients take other meds that lower the seizure threshold.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Check your client’s med sheet for valproate; if both drugs are listed, confirm the lamotrigine dose is half the usual speed.
02At a glance
03Original abstract
Information about the mechanism of action and pharmacology of lamotrigine is summarized. A brief review of the literature on the use of this drug in people with intellectual disability is followed by a suggested framework for evaluating antiepileptic drugs in this population. The role of lamotrigine is systematically examined against the suggested framework. This leads to the conclusion that lamotrigine is a very favourable drug for treating epilepsy in people with intellectual disability because it has a broad spectrum of action, is effective in treating subtle seizures, shows no loss of effect with time, is not usually sedative, does not produce difficult-to-manage adverse effects, appears to have no direct adverse behavioural effects and is available in a range of 'patient friendly' preparations. However, it is important to use the drug wisely. This implies starting with low doses of lamotrigine and escalating the dose slowly to avoid adverse effects, especially rash, and being aware of drug interactions which could cause difficulty, including the prolongation of half-life with valproate, the pharmacodynamic interaction when it is added to carbamazepine and the pharmacokinetic interactions of lamotrigine with a number of antiepileptic drugs.
Journal of intellectual disability research : JIDR, 1998 · doi:n/a